15 Years of heart-failure trials: What have we learned?

Lancet

Volumn 352, Issue SUPPL.1, 1998, Pages 29-33

  Massie, Barry M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; VASODILATOR AGENT;

CLINICAL TRIAL; HEART FAILURE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0031661530     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90016-2     Document Type: Article

References (33)

1. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52.
2. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in post-infarction patients with early reduction of ejection fraction. Circulation 1991; 83: 52-60.
3. The Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Eur Heart J 1984; 5: 516-28.
4. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.
5. Packer M, Rouleau J, Swedberg K, Pitt B, Fisher L, Klepper M. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation 1993; 88 (suppl I): I-310 (abstr).
6. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
7. Captopril Multicenter Research Group. A placebo controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2: 755-63.
8. Newman TJ, Maskin CS, Dennick LG, Meyer JH, Hallows BG, Cooper WH. Effects of captopril on survival in patients with heart failure. Am J Med 1988; 84 (suppl 3A): 140-44.
9. The CONSENSUS Trial study group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
12. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-77.
13. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-28.
14. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
15. Results of the Assessment Trial of Lisinopril and Survival Trial (ATLAS). Presented at the 47th Annual Scientific Session of the American College of Cardiology, Atlant, GA, April 29, 1998.
16. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
17. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 1989; 320: 677.
18. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED Trial. J Am Coll Cardiol 1993; 22: 955-62.
19. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensinconverting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
20. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
21. The Xamoterol in Severe Heart Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
22. Dies F, Knell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986; 74 (suppl II): II-38 (abstr).
23. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomized study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349: 971-77.
24. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
25. Ferguson JJ. Meeting highlights: American Heart Association 69th Scientific Session, New Orleans, LA, November 10-13, 1996. Circulation 1997; 95: 761-64.
26. Lubsen J, Just H, Hjalmarsson AC, Framboise D, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main sults from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223-31.
27. Feldman AM. Classification of positive inotropic agents. J Am Coll Cardiol 1993; 22: 1223-27.
28. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1442-46.
29. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
30. Packer M, Bristow MR, Cohn IN, et al. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996; 334: 1349-55.
31. Australia/New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
32. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16.
33. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993; 149-55.